NEW YORK, May 27, 2015 /PRNewswire/ -- Immune
Pharmaceuticals ("Immune" or the "Company") (NASDAQ: IMNP) will
present at the following two conferences this week:
Marcum Microcap Conference, May 28,
2015, at 1:30 p.m. EDT in the
Uris Room at the Grand Hyatt New York.
Sachs Immuno-Oncology BD&L and Investment Forum in
Chicago, May 29, 2015, at 2:10 pm
CDT in Room B at the Hyatt Chicago Magnificent Mile.
At the Marcum Conference, Dr. Daniel
Teper, CEO of Immune, will provide a strategic, financial
and operational update for investors.
During the Sachs Immuno-Oncology BD&L and Investment Forum,
Dr. Teper will discuss the development and partnering strategy for
NanomAbs, its antibody nanoparticle conjugate platform for the
targeted delivery of chemotherapeutics. Immune recently announced a
partnership with STC Biologics for the development of anti-HER2
paclitaxel NanomAbs as well as other development candidates
leveraging additional chemotherapeutics and monoclonal
antibodies.
Both presentations will be available at
www.immunepharmaceuticals.com.
On May 26, 2015, Immune celebrated
its new global headquarters at the Alexandria Center for Life
Science in New York City and the
company's listing on NASDAQ with the ringing of the closing bell of
the exchange.
About Immune Pharmaceuticals Inc.
Immune Pharmaceuticals Inc. applies a personalized approach to
treatment, developing novel, highly-targeted antibody therapeutics
to improve the lives of patients with inflammatory diseases and
cancer. The Company's lead product candidate, bertilimumab, is in
clinical development for moderate to severe ulcerative colitis and
Crohn's disease as well as bullous pemphigoid, an orphan
auto-immune dermatological condition. Immune licensed worldwide
rights for systemic indications of bertilimumab from iCo
Therapeutics (TSX: ICO; OTCQX: ICOTF) in June 2011, while iCo retained rights to all
ophthalmic indications. iCo originally licensed the exclusive
world-wide rights to bertilimumab in 2006 from MedImmune, the
Global Research and Development arm of AstraZeneca. Immune's
pipeline also includes NanomAbs, antibody nanoparticle conjugates,
for the targeted delivery of chemotherapeutics, and AmiKet, a
Neuropathic Pain drug candidate ready for Phase III. AmiKet has
received Orphan Drug Designation for Post Herpetic Neuralgia.
For more information, visit Immune's website at
www.immunepharmaceuticals.com, the content of which is not a part
of this press release.
About STC Biologics
STC Biologics, Inc. is a biotechnology company with laboratories
in Cambridge, MA USA focusing on development of biologics
and complex products. STC's drug portfolio includes a diversified
mix of biosimilars and novel biologics. STC's bioservices group
caters to wider product classes, including peptides, RNA and
liposomal products, in addition to complex glycoproteins and
biosimilars. STC's core competency is in generating biologic drugs
with specific product attributes through innovations in process
development and understanding structure-activity-relationships.
STC's team has brought several biologics to global regulatory
approvals, with more than fifty years of collective experience in
drug development.
Forward-Looking Statements
This news release and any oral statements made with respect to
the information contained in this news release contain
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. You are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal" or the negative of
those words or other comparable words to be uncertain and
forward-looking. Such forward-looking statements include
statements that express plans, anticipation, intent, contingency,
goals, targets, future development and are otherwise not statements
of historical fact. These statements are based on our current
expectations and are subject to risks and uncertainties that could
cause actual results or developments to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. Factors that may cause
actual results or developments to differ materially include, but
not limited to: the risks associated with the adequacy of our
existing cash resources and our ability to continue as a going
concern; the risks associated with our ability to continue to meet
our obligations under our existing debt agreements; the risk that
clinical trials for bertilimumab or AmiKet will not be successful;
the risk that bertilimumab, AmiKet or compounds arising from our
NanomAb program will not receive regulatory approval or achieve
significant commercial success; the risk that we will not be able
to find a partner for AmiKet on attractive terms, on a timely basis
or at all; the risk that our other product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later-stage clinical
trials; the risk that we will not obtain approval to market any of
our product candidates; the risks associated with dependence upon
key personnel; the risks associated with reliance on collaborative
partners and others for further clinical trials, development,
manufacturing and commercialization of our product candidates; the
cost, delays and uncertainties associated with our scientific
research, product development, clinical trials and regulatory
approval process; our history of operating losses since our
inception; the highly competitive nature of our business; risks
associated with litigation; and risks associated with our ability
to protect our intellectual property. These factors and other
material risks are more fully discussed in our periodic reports,
including our reports on Forms 8-K, 10-Q and 10-K and other filings
with the U.S. Securities and Exchange Commission. You are urged to
carefully review and consider the disclosures found in our filings
which are available at www.sec.gov or at
www.immunepharmaceuticals.com. You are cautioned not to place undue
reliance on any forward-looking statements, any of which could turn
out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties or other risk factors. We expressly disclaim any
obligation to publicly update any forward looking statements
contained herein, whether as a result of new information, future
events or otherwise, except as required by law.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immune-pharmaceuticals-to-present-at-sachs-immuno-oncology-business-development-bdl-and-investment-forum-in-chicago-and-at-marcum-conference-in-new-york-300089695.html
SOURCE Immune Pharmaceuticals Inc.